Core Viewpoint - The lawsuit involving BeiGene and Pharmacyclics has been voluntarily withdrawn, resulting in no negative impact on the company's operations or product development in the U.S. market [2][5][4]. Group 1: Lawsuit Details - On June 13, 2023, Pharmacyclics LLC filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming patent infringement related to the product 百悦泽? [3]. - The patent in question is U.S. Patent No. 11,672,803, which was granted to Pharmacyclics on the same day the lawsuit was filed [3]. - The court has agreed to pause the infringement lawsuit pending the outcome of a Patent Trial and Appeal Board (PTAB) review, which is expected to conclude by November 1, 2023 [3]. Group 2: Impact on the Company - The lawsuit has not adversely affected the research and sales of 百悦泽? in the U.S. market, nor has it significantly impacted the company's overall operations [5]. - The company maintains confidence in its intellectual property related to 百悦泽? and plans to continue developing innovative cancer treatment solutions [2][5].

Core Points - BeiGene announced the grant of a total of 36,000 restricted stock units to 237 grantees under the 2016 option and incentive plan [1] - Additionally, one grantee was awarded a total of 2,935 performance stock units [1] - The total restricted stock units and performance stock units correspond to 509,197 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Points - BeiGene (06160) announced that on September 30, 2025, the Board's Compensation Committee granted a total of 36,000 restricted stock units involving American Depositary Shares to 237 grantees under the 2016 Option and Incentive Plan [1] - Additionally, one grantee was awarded 2,935 performance stock units involving American Depositary Shares [1]

Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units and performance stock units to 237 recipients, totaling 36,000 American Depositary Shares (ADS) [1] Summary by Categories - **Stock Grants** - The board's compensation committee granted a total of 36,000 restricted stock units to 237 recipients [1] - Additionally, one recipient was awarded 2,935 performance stock units [1] - **Equity Impact** - The restricted stock units and performance stock units correspond to 509,197 shares, which represents approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - BeiGene (06160) announced the grant of restricted stock units and performance stock units to its employees as part of its 2016 option and incentive plan, indicating ongoing commitment to employee incentives and retention [1] Summary by Categories Company Actions - The board's compensation committee granted a total of 36,000 American Depositary Shares (ADS) in restricted stock units to 237 grantees [1] - Additionally, one grantee received 2,935 ADS in performance stock units [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年9月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百三十七名承授人授 出涉及合共36,234股美國存託股份的受限制股份單位，並向一名承授人授出涉及 合共2,935股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的受限制股份單位及業績股份單位 於2025年9月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 三十七名承授人合共36,234股美國存託股份受限制股份單位，並向一名承授人授 出合共2,935股美國存託股份業績股份單位。該等受限制股份單位及業績股份單位 相當於509,197股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

Core Viewpoint - Pharmacyclics LLC has decided not to appeal the final written decision from the USPTO regarding the patent dispute with BeiGene, leading to the voluntary withdrawal of the lawsuit by both parties [1][4]. Group 1: Legal Proceedings - On June 13, 2023, Pharmacyclics filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming that the product Brukinsa infringed on its US patent No. 11,672,803 [4]. - The court agreed to suspend the infringement lawsuit pending the outcome of BeiGene's application for a post-grant review (PGR) of the '803 patent, which is due by November 1, 2023 [4]. - On April 29, 2025, the USPTO declared the '803 patent invalid, and Pharmacyclics had the option to appeal this decision [4][5]. Group 2: Financial Performance - In the first half of 2025, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and achieved a net profit of 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year [7]. - The majority of BeiGene's revenue came from international markets, with overseas sales of Brukinsa reaching 11.335 billion yuan, accounting for 65.3% of total revenue, while sales in China were 1.192 billion yuan [7]. Group 3: Historical Financials - From 2017 to 2020, BeiGene experienced significant net losses, with figures of 982 million yuan, 4.747 billion yuan, 6.915 billion yuan, and 11.384 billion yuan respectively [5]. - The company continued to incur losses from 2021 to 2023, with net losses of 9.748 billion yuan, 13.642 billion yuan, and 6.716 billion yuan [5].

A 股代码：688235 A 股简称：百济神州 公告编号：2025-036 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况及最新进展 2023 年 6 月 13 日，Pharmacyclics LLC 公司（作为申诉方，以下简称 "Pharmacyclics"）在美国特拉华州地方法院对百济神州有限公司（以下简称 "公司"）及公司全资子公司 BeOne Medicines USA, Inc（. 前称 BeiGene USA, Inc.） （作为被申诉方）提出申诉，声称公司产品百悦泽®侵犯了其于 2023 年 6 月 13 日授权的美国专利编号为 11,672,803 的专利（以下简称"'803 专利"），并请 1 案件所处的诉讼阶段：双方已向法院提交一份共同协议，自愿撤回案件， 案件已做出终局处理。 公司所处的当事人地位：本次诉讼的被申诉方。 是否会对公司损益产生负面影响：本次诉讼 ...

Core Viewpoint - Technological innovation is crucial for the transformation and development of industries, with A-share listed companies increasing their R&D investments significantly, reflecting a shift towards high-quality growth driven by technology [1][2]. Group 1: Overall R&D Investment - In 2024, the total R&D expenditure of A-share listed companies reached 1.62 trillion yuan, a year-on-year increase of 3.1% [2]. - A-share companies account for over half of the total R&D spending by all enterprises in China, with companies on the Sci-Tech Innovation Board showing a notable 7.9% increase in R&D expenses [2]. Group 2: R&D Investment Trends - The sustainability of R&D investment is a key indicator of a company's technological innovation strength and ability to convert technology into productivity [2]. - From 2022 to 2024, 1,535 A-share companies, representing 28.4% of the total, have increased their R&D investments for three consecutive years, indicating a strong trend towards innovation [2]. Group 3: Industry Distribution of R&D Investment - The 1,535 companies are spread across 30 industries, with the electronics sector leading with 212 companies (13.81%), followed by machinery (201 companies, 13.09%) and power equipment (146 companies, 9.51%) [3]. - This distribution highlights the critical role of technological innovation in transforming traditional manufacturing and promoting high-quality development [3]. Group 4: Top R&D Investors - BYD (002594.SZ) leads with R&D spending of 53.195 billion yuan in 2024, a year-on-year increase of over 10 billion yuan [4]. - China Power Construction (601669.SH) ranks second with 24.25 billion yuan in R&D investment, while China Petroleum (601857.SH) and others follow, collectively investing around 210 billion yuan [4]. Group 5: Notable Companies and Their Innovations - BYD's R&D investment increased by 35.68% to approximately 53.2 billion yuan, with significant advancements in electric vehicles and smart technologies [6]. - China Power Construction focuses on green development and technology innovation, with 24.2 billion yuan in R&D, contributing to clean energy transitions [7]. - China Petroleum's R&D investment of 23 billion yuan reflects its commitment to overcoming key technological challenges in the oil and gas sector [8]. - CATL (宁德时代) invested 18.6 billion yuan in R&D, emphasizing its leadership in battery technology and smart manufacturing [9]. - Midea Group's R&D spending of 16.2 billion yuan supports its strategy of technological leadership and organizational transformation [10].